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years. Of these PFCs, perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) are end products in the environment (Starkov and Wallace 2002; Olsen et al. 2004; Nakayama et al. 2005) . Due to resistance to biodegradation in the ecological system and amphilic nature, they are biomagnified in humans as well as wild animals (Giesy and Kannan 2001; Jin et al. 2004; Kannan et al. 2004; Morikawa et al. 2006) . Human serum levels have been shown to be increasing significantly in recent years, raising an alarming concern about the effects on human health (Jin et al. 2004; ).
Toxicological evaluations have revealed that these chemicals have a potent anorexic effect in rodents and monkeys Seacat et al. 2002) .
Austin et al recently reported that PFOS inhibited food consumption and body weight gain, and is accumulated specifically in hypothalamus (Austin et al. 2003) . With these pieces of evidence and their structural mimicry of natural medium-size free fatty acids, one may reasonably hypothesize that PFOS and PFOA inhibit food consumption and body weight gains through direct action on the satiety center. Since this center controls not only eating behavior but also bridges energy homeostasis with emotion, this effect on the satiety center is critically important for a proper evaluation of the hazard potential of these chemicals (Kishi and Elmquist 2005) .
The primary aim of the present study is to characterize the toxic of PFOS and PFOA on the satiety center. To address the question of whether or not PFOS and PFOA have direct action on hypothalamus, we dosed animals by 6 intracerebroventricular (ICV) administration and evaluated not only eating behavior but also gut motility as a peripheral signal from the hypothalamus.
Materials and Methods
Animals and chemicals
The study protocol was approved by the Animal Research Ethics Committee of Kyoto University's Institutional Review Board. Animals were kept and handled according to the guideline of the Animal Research Committee, Graduate School of Medicine, Kyoto University.
We used male ddy mice (34-37 g, 8-9 weeks of age;
Japan SLC Inc., Shizuoka, Japan), and male Wistar rats (230-280 g, 8-10 weeks of age;
CLEA Japan Inc., Tokyo, Japan). The mice and rats were housed individually in a regulated environment (24 2 o C, 50 10% humidity, 14:10 h light:dark cycle with light on at 7:00 a.m.). Food and water were available ad libitum except as indicated. 
ICV Substance Application
For ICV administration, the mice were anesthetized with sodium pentobarbital (80-85 mg/kg IP) and placed in a stereotaxic instrument 7 days before experiments. A hole was made in each mouse's skull using a needle inserted 0.9 mm lateral to the central suture and 0.9 mm posterior to the bregma. A 24-gauge cannula (Safelet-Cas, Nipro Corp., Osaka, Japan) beveled at one end over a distance of 3 mm was implanted into the third cerebral ventricle for ICV administration. The cannula was fixed to the skull using dental cement and capped with silicon without an obtruder. A 27-gauge administration insert was attached to a microsyringe using PE-20 tubing.
To evaluate gastroduodenal motility, rats were anesthetized using sodium pentobarbital (50 mg/kg IP), placed in a stereotaxic apparatus, and implanted with a guide cannula (25-gauge; Eicom Corp., Kyoto, Japan), which reached the right lateral ventricle. The stereotaxic coordinates were 0.8 mm posterior to the bregma, 1.5 mm right lateral to the midline, and 3.5 mm below the outer surface of the skull. The guide cannula was secured using dental cement and anchored by 2 stainless steel screws fixed on the dorsal surface of the skull. After surgery, a dummy cannula (Eicom Corp.) was inserted into each guide cannula, and a screw cap (Eicom Corp.) was placed on the guide cannula to prevent blockage. The animals were allowed to recover for 7 days after this operation.
Feeding Tests
Before the feeding tests, mice were deprived of food for 16 h with free access to water. A standard diet (F-2, 3.73 kcal/g, Funahashi Farm Corp., Chiba, Japan) was used. For food-deprived mice, drugs were administered at 10:00 a.m. The drug was dissolved in ACSF containing 1% DMSO to a final volume of 4 µl for ICV administration. Food intake was measured by subtracting uneaten food from initially premeasured food at 20 min, 1 h, 2 h, 4 h, 12 h and 24 h after administration and checking the food spillage.
Gastroduodenal Motility
Gastroduodenal motility was measured in conscious freely moving rats by the manometric method. At 7 days after the brain surgery, the rats were deprived of food and given free access to water for 16 h prior to the abdominal operation. They were anesthetized with pentobarbital sodium (50 mg/kg IP). Next, a motility recording device was implanted as follows. Two open-tipped catheters (3-Fr, 1-mm diameter;
Atom Medical Corp., Tokyo, Japan) were inserted into the gastric body and duodenum for manometric measurement, with their tips placed at the gastric antrum and 3 cm distal from the pylorus. The catheters were held in place by purse-string sutures at the point of exit from the gastric and duodenum walls, brought out together through the abdominal wall musculature, tunneled subcutaneously to the back of the neck and sutured to the skin. After 1 week, the animals were subjected to a 16-h fast prior to the commencement of the experiment. On the day of the experiment, a manometric catheter was connected to a pressure transducer (TP-400T; Nihon Kohden Corp., Tokyo, Japan) and connected to an infusion swivel (dual type, 20-gauge; Instech Laboratories Inc., PA, USA) to allow free movement. The catheter was continuously infused with bubble-free 0.9% saline at a rate of 1.5 mL/h by using a low compliance capillary infusion system with a heavy-duty pump (CVF-3100; Nihon Kohden Corp.).
The PFOS (300 µg/kg) was dissolved in ACSF containing 1% DMSO to a final volume of 10 µl for ICV administration.
Gastric Emptying
Before the experiments for gastric emptying, mice were deprived of food for 16 h with free access to water. The fasted mice had free access to pre-weighed pellets for 1 hour; they were then intracerebroventricularly administered PFOS (100-300 µg/kg) or vehicle. The mice were deprived of food again for 2 h after administration. Food intake was measured by weighing the uneaten pellets. Mice were sacrificed by cervical dislocation 3 h after the start of experiments. Immediately after, the stomach was exposed by laparotomy, quickly ligated at both the pylorus and cardia, then removed;
at this point the dry content was weighed. Contents were dried using a vacuum freeze Cy3-labeled anti-rabbit IgG (Chemicon International Inc.) diluted to 1:1000 and then observed under laser scanning microscopy (LSM 510; Carl Zeiss Inc. Japan, Tokyo, Japan).
Statistical Analysis
ANOVA followed by Scheffe's method was used to assess differences among groups.
Results are expressed as the mean value SE. P < 0.05 was considered to be statistically significant.
Results
Anorexigenic activity of PFOS and PFOA.
To investigate whether PFOS and PFOA influence feeding behavior, we first examined the effects of ICV administration of PFOS (10-300 µg/kg) on feeding in food-deprived mice. Centrally administered PFOS produced significant inhibitory feeding behavior in a dose-related manner (Figure 1 ). Cumulative food intake was significantly decreased in the first 1 h after ICV administration and remained significantly decreased for a period of 24 h. PFOA (300 µg/kg) was found to be as anorexic as PFOS (data not shown). During the observed periods, mice were conscious and neither seizure nor sedation occurred.
Influences of PFOS on gut motility.
Using conscious freely moving rat models, we examined whether or not PFOS influences gastroduodenal motility. ICV administration of PFOS (300 µg/kg) disrupted the fasted motor activity in the antrum and duodenum in food-deprived rats (Figure 2) .
The fed-like motor pattern induced by PFOS continued for over 1 h both in the stomach and duodenum (n = 3-5). In addition, centrally administered PFOS (100-300 µg/kg) decreased the gastric emptying rate 2 h after its administration in a dose-related manner (Figure 3 ).
Specific increases in urocortin 2 mRNA in hypothalamus by PFOS.
We examined the gene expression of hypothalamic neuropeptides in food-deprived mice following an ICV infusion of PFOS to evaluate the possibility that PFOS acts via the hypothalamic pathway. Real-time RT-PCR analysis showed that PFOS significantly increased the expression of urocortin 2 by 146% compared with the controls (Figure 4) . On the other hand, PFOS significantly decreased orexin and Finally, we tested whether the inhibitory effect on feeding of PFOS (300 µg/kg) was blocked by the ICV administration of the selective corticotropin-releasing factor type 2 receptor (CRFR2) antagonist antisauvagine-30 (29.6 µg/kg) ( Figure 6 ).
Antisauvagine-30 was confirmed to attenuate the inhibitory effect of PFOS on eating, suggesting that increased urocortin 2 signals suppressed peripheral signals to the gut through its receptor, CRFR2.
Discussion
In this study, it is clearly demonstrated that PFOS and PFOA have anorexic activity. The anorexic effect of PFOS is mediated by its direct effect on the hypothalamus through upregulation of urocortin 2. Urocortin 2 mediated its effect through binding the receptor CRFR2 in PVN. This generated signal inhibited gut motility through afferent pathway. Taken together, PFOS inhibited eating behavior and modulated gut motility through a direct effect on the brain. This is the first report on toxicological activity in the hypothalamus by ubiquitous environmental toxicants in humans or animals.
Urocortin was found in 1995 as the second ligand for the CRF receptors (Vaughan et al. 1995) . While CRF is mainly involved in the regulation of stress-related behavior and colonic motility, urocortin is mainly involved in the regulation of feeding behavior and gastric motility (Asakawa et al. 1999; Dautzenberg and Hauger 2002) . Urocortin 2 was identified in 2001 as an endogenous ligand for CRFR2 (Hsu and Hsueh 2001; Reyes et al. 2001 ). The urocortin 2 gene is abundantly expressed in the hypothalamic nuclei, including the PVN, that are involved in the regulation of feeding and gut motility. Previous studies have shown that urocortin 2 suppresses food intake and delays gastric emptying (Hsu and Hsueh 2001; Czimmer et al. 2006 ). In addition, stimulation of the CRF2 receptor with urocortin 2 induces anxiogenic responses in a wide variety of rodent anxiety models (Bruijnzeel and Gold 2005) . The involvement of CRFR2 was substantiated by a finding that selective CRFR2 antagonist antisauvagine-30 attenuated PFOS anorexic activity. These data collectively suggest PFCs may modulate not only eating behavior but also changes in mood.
Upregulation of urocortin 2 expression by the administration of PFOS was unexpected and its mechanism remains an enigma. Although it is a member of the urocortin gene family, urocortin 2 seems to be unique in its regulation. Its promoter region is shorter than those of other members. Bioinformatic analysis (http://bimas.dcrt.nih.gov/molbio/signal/) reveals that urocortin 2 gene has TATA, GATA and GR elements but lacks a CRE element, which is commonly found in the promoters of the other members and provides responsiveness to cyclic AMP (Zhao 1998 ). It has also been shown recently that urocortin 2 decreases the cytosolic Ca concentration by closing L-type Ca channels (Tao 2006 ). On the other hand, PFOS and PFOA have been shown to change the surface charge of the plasma membrane toward a less negative side and perturb L-type Ca2 + channel properties Matsubara et al. 2006) . We thus hypothesize that perturbation of Ca-channel dynamics after ICV administration of PFOS might somehow be linked to the exaggerated response of urocortin 2 neurons. Further study is warranted for determining the mechanisms of the upregulation of urocortin 2.
It has been reported that repeated dosing with PFOS by the intraperitoneal route also inhibits food intake in rodents and monkeys Seacat et al. 2002) . Considering that both PFOS and PFOA have demonstrated a high affinity to PPAR-a (Vanden Heuvel et al. 2006) , feeding is inhibited by an afferent pathway from the gut in addition to the efferent pathway by urocortin 2. By analogy to endogenous oleylethanolamide (OEA), which has a potent binding affinity to peroxisome proliferator-activated receptor-a (PPAR-a), PFOS and PFOA may also inhibit food intakes by the afferent pathway (Fu et al. 2003; Proulx et al. 2005) . The putative afferent pathway remains entirely unknown worth pursuing.
PFOS and PFOA have been found in human serum samples from various countries as well as wild animals (Giesy and Kannan 2001; Jin et al. 2004; Kannan et al. 2004; Morikawa et al. 2006) . The toxicological profile of PFOS and PFOA include carcinogenicity and developmental toxicity in animals (Kennedy et al. 2004; Lau et al. 2004; Luebker et al. 2005; Olsen et al. 2005 ). An epidemiological study suggested these chemicals are associated with elevated carcinogenicity risks (Alexander et al. 2003) . In addition to the common toxicological profile, we have demonstrated that these chemicals have a toxic effect on PVN. Thus persistent PFCs can be characterized as having certain common properties: persistency in the ecological system, mimicry of natural fatty acids and an amphilic character. These common properties may be used to classify a new subgroup of "anorexigens", in like manner that chemicals which induce obesity are called "obesitogens".
In conclusion, this study indicates that PFOS and PFOA act centrally to suppress food intake. Their mechanism of action involves the activation of hypothalamic urocortin 2 and CRFR2 and the suppression of gastroduodenal motor activity. These observations indicate that PFCs may act centrally to influence not only eating behaviors but also mood. We believe that the accumulating evidence of such pleiotropic effects strongly suggests there is a need for further efforts to reduce the level of PFCs now found ubiquitously throughout the world. 
